Israel - Ibrani - Ministry of Health

csl behring ltd., israel - human-rabies immunoglobulin - תמיסה להזרקה - human-rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - prophylaxis of rabies.

Israel - Ibrani - Ministry of Health

kamada ltd, israel - human-rabies immunoglobulin - תמיסה להזרקה - human-rabies immunoglobulin 150 iu/ml - rabies immunoglobulin - rabies immunoglobulin - kamrab im is indicated for passive, transient post-exposure prevention of rabies infection when given immediately to individuals in cases of contact with rabid or possibly rabid animal.

Israel - Ibrani - Ministry of Health

neopharm scientific ltd - a/california/7/2009 (h1n1)pdm09-like virus; a/hong kong/4801/2014 (h3n2) - like virus; b/brisbane/60/2008 - like virus - תרחיף להזרקה - b/brisbane/60/2008 - like virus 15 mcg / 0.5 ml; a/hong kong/4801/2014 (h3n2) - like virus 15 mcg / 0.5 ml; a/california/7/2009 (h1n1)pdm09-like virus 15 mcg / 0.5 ml - vaccinia immunoglobulin - vaccinia immunoglobulin - active immunisation against influenza in theelderly (65 years of age and over), especially for those with an infreased risk of associated complications (i.e. patients affected by underlying chronic diseases including diabetes, cardiovascular and respiratory diseases).

Israel - Ibrani - Ministry of Health

kamada ltd - cytomegalovirus antibody 50 iu/ml; human plasma protein 100 mg/ml - solution for injection - cytomegalovirus immunoglobulin - prophylaxis of clinical manifestations of cytomegalovirus infection in patients subjected to immunosuppressive therapy, particularly in transplant recipients.

Israel - Ibrani - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 100 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Israel - Ibrani - Ministry of Health

abbvie biopharmaceuticals ltd, israel - palivizumab 50 mg - powder for solution for injection - palivizumab - is indicated for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (rsv). safety and efficacy were established in infants with bronchopulmonary dysplasia (bpd) and in infants with a history of prematurity (35 weeks gestational age) and in children less then 2 years of age,with haemodynamically significant congenital heart disease.

Israel - Ibrani - Ministry of Health

astrazeneca (israel) ltd - palivizumab - תמיסה להזרקה - palivizumab 100 mg/ml - palivizumab

Israel - Ibrani - Ministry of Health

cure medical & technical supply - rabbit immunoglobulin - תרכיז להכנת תמיסה לאינפוזיה - rabbit immunoglobulin 20 mg/ml - rabies immunoglobulin

Israel - Ibrani - Ministry of Health

merck sharp & dohme israel ltd - bezlotoxumab - תרכיז להכנת תמיסה לאינפוזיה - bezlotoxumab 25 mg / 1 ml - bezlotoxumab

Israel - Ibrani - Ministry of Health

kamada ltd, israel - cytomegalovirus antibody; human plasma protein; immunoglobulins, normal human - תמיסה לאינפוזיה - immunoglobulins, normal human 96 %; human plasma protein 50 mg/ml; cytomegalovirus antibody 100 u/ml - cytomegalovirus immunoglobulin